All In Biotech

Drug Trial Radar · NCT07146022

Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Dose Study to Evaluate the Efficacy and Safety of VDPHL01 in Female Subjects With Androgenetic Alopecia

Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 552 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

552

Planned (sponsor's estimate)

Start

Jul 25, 2025

Primary completion

Jun 2027

Study completion Jan 2028

Sponsor

Lead sponsor
Veradermics, Inc.Industry
Sponsor type
Industry
First posted
Aug 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and efficacy of VDPHL01 in female subjects with Androgenetic Alopecia (AGA). AGA is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormones) that causes hair loss. VDPHL01 is an investigational oral drug to treat AGA. This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, month 2, month 4, month 6, month 8, month 10, month 12, month 13).

Conditions

  • Androgenetic Alopecia (AGA)
  • Androgenetic Alopecia
  • AGA
  • Female Androgenetic Alopecia
  • Hair Loss

Interventions

  • VDPHL01 QDDrug

    VDPHL01 Extended Release (ER) Tablet

  • PlaceboDrug

    Placebo tablet

  • VDPHL01 BIDDrug

    VDPHL01 Extended Release (ER) Tablet

  • PlaceboDrug

    Placebo tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in non-vellus Target Area Hair Counts (TAHC)Time frame: Month 6
  2. Subjects Evaluation of Treatment BenefitTime frame: Month 6

Locations

71 sites in 1 country. Site status is shown where the registry gives one.

  • Site 73

    Birmingham, Alabama

  • Site 89

    Birmingham, Alabama

  • Site 77

    Phoenix, Arizona

  • Site 30

    Fort Smith, Arkansas

  • Site 69

    Encino, California

  • Site 2

    Fremont, California

  • Site 64

    Manhattan Beach, California

  • Site 93

    Northridge, California

  • Site 66

    Santa Monica, California

  • Site 34

    Sherman Oaks, California

  • Site 94

    Thousand Oaks, California

  • Site 21

    Vista, California

  • Site 5

    Castle Rock, Colorado

  • Site 24

    Greenwood Village, Colorado

  • Site 17

    Aventura, Florida

  • Site 71

    Boca Raton, Florida

  • Site 86

    Coral Gables, Florida

  • Site 62

    Coral Gables, Florida

  • Site 99

    Miami, Florida

  • Site 54

    Ocala, Florida

  • Site 43

    Atlanta, Georgia

  • Site 90

    Sandy Springs, Georgia

  • Site 31

    Boise, Idaho

  • Site 61

    Chicago, Illinois

  • Site 53

    Clarksville, Indiana

  • Site 15

    Indianapolis, Indiana

  • Site 32

    New Albany, Indiana

  • Site 55

    Plainfield, Indiana

  • Site 27

    West Lafayette, Indiana

  • Site 79

    Leawood, Kansas

  • Site 52

    Louisville, Kentucky

  • Site 41

    Baton Rouge, Louisiana

  • Site 13

    Covington, Louisiana

  • Site 12

    Metairie, Louisiana

  • Site 75

    New Orleans, Louisiana

  • Site 84

    Glenn Dale, Maryland

  • Site 87

    Rockville, Maryland

  • Site 22

    Brighton, Massachusetts

  • Site 80

    Chestnut Hill, Massachusetts

  • Site 59

    Quincy, Massachusetts

Showing 40 of 71 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.